Definitive Contract 75F40122C00182
Award Date
9/21/22
Potential Completion Date
9/29/26
Potential Value
$1.8M
Federal Agency
Food and Drug Administration
Awardee
University Of Florida
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a firm-fixed-price purchase order to Simulations Plus Inc., a for-profit software company specializing in pharmaceutical modeling and simulation. The contract, valued at $109,798.77, is for the purchase of 50 GastroPlus licenses, 30 IVIVCPlus module licenses, and 30 PBPK Plus licenses. The contract has no set-aside designation and is not associated with a larger contract vehicle. Simulations Plus has previously provided similar software...
This is a $500,000 firm-fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to the University of Florida (UF) Division of Sponsored Research for a pharmacokinetic comparison study of locally acting orally inhaled drug products. The contract does not have a set-aside designation, indicating UF competed for and was awarded the contract based on its extensive research capabilities. UF is a major research institution that provides a wide range of goods and services to...
The University of Connecticut (UConn) was awarded a $1,310,263 cost-no-fee definitive contract by the Food and Drug Administration (FDA) to enhance and validate in vitro-in vivo correlation (IVIVC) methods for long-acting injectable drug products to accelerate their generic development. The contract is part of the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various areas to modernize regulatory science and support...
This federal contract award, identified as HHSF223201610099C, was made by the Food and Drug Administration (FDA) to the University of Florida (UF) Division of Sponsored Research. The contract, valued at $764,975.37, is for a Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products. This work falls under the FDA's Broad Agency Announcement (BAA) program for this research area. The contract is a definitive, cost-no-fee contract, with a performance period ending on March 22,...
This is a firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Simulations Plus Inc. for an annual software license for one user to access the company's ADMET and GastroPlus modeling and simulation software. The total ceiling value of the contract is $96,898.01 and the ultimate completion date is January 31, 2026. The software provided under this award supports pharmaceutical drug research, development, and regulatory assessment through...
The U.S. Food and Drug Administration (FDA) awarded a 4-month, $24,480 firm-fixed-price (FFP) purchase order to the University of Florida (UF) Division of Sponsored Research to provide training courses for the FDA's Center for Drug Evaluation and Research (CDER), Office of Clinical Pharmacology (OCP) to support its Advanced Model-Informed Drug Development (MIDD) program. This purchase order is not associated with a larger contract vehicle and does not have a set-aside designation. As a major...
The Department of Health and Human Services Food and Drug Administration awarded a $921,732.78 firm fixed-price definitive contract to the University of Florida's Division of Sponsored Research to conduct research on the "Systematic Evaluation of the Ex-Throat Plume Properties of MDI Formulations." The contract does not have any set-aside designation. As a public land-grant research university, the University of Florida has extensive experience providing research, development, testing,...
This is a $749,980 firm fixed price contract awarded by the Food and Drug Administration (FDA) to the University of Florida (UF) to develop a "TERATOGENIC RISK IMPACT AND MITIGATION (TRIM): AN EVIDENCE-BASED DECISION FRAMEWORK". The contract has no set-aside designation. UF, through its Division of Sponsored Research, will lead the effort which includes clinical expertise from a subcontractor, The Johns Hopkins University. This contract was awarded under the FDA's Broad Agency...
This is a definitive cost-no-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of Florida's Institute of Food and Agricultural Sciences. The $4,489,146.36 contract is for the development of a "multipotential mitigation agent for gastrointestinal syndrome" under the FGP-P program. The contract has a period of performance that runs through March 8, 2022, and does not have a set-aside designation. The University...
The U.S. Food and Drug Administration (FDA) awarded a firm fixed price purchase order to Certara UK Limited, doing business as Certara, a for-profit limited liability company, for SIMCYP software licenses and maintenance support. The $114,316.00 contract will allow the FDA's Office of Clinical Pharmacology Drug Reviewers to complete their review of investigational new drugs. Certara has previously provided this physiologically-based pharmacokinetic modeling software to the FDA and...